Every time a cell divides, the protective caps on the ends of its chromosomes, known as telomeres, get shorter. Once those caps become too short, the cell stops dividing. Cancer cells dodge this limit: most of them switch on the enzyme telomerase, which rebuilds telomeres, but roughly one tumor in ten takes a different route, one that resembles mending a frayed rope with a neighboring strand. In this alternative mechanism, known as ALT, the protein PIF1 plays a key role.
PIF1 works like a guard on a DNA construction site. For one thing, it untangles the knots that form out of four guanine strands and block chromosome copying. These knots, called G-quadruplexes, crop up especially often in telomeres. For another, PIF1 throws fuel on the fire itself: it sets off a process in which the cell copies long stretches of DNA, using a break as its starting point. That is exactly how ALT cells lengthen telomeres and produce extra ring-shaped DNA fragments that float around in the nucleus.
Experiments showed that PIF1 is not merely present in the cell: it actively travels to damaged telomeres. To see this, the scientists built a system that lets them create breaks specifically in telomeres on command. Within minutes of a break, PIF1 piled up at that spot. When PIF1 was switched off, however, cells accumulated G-quadruplexes across the whole genome, and production of ring-shaped DNA fragments fell by more than half.
This work changes how we think about the way cancer cells choose to survive. PIF1 used to be seen as just an accessory protein that helps with DNA copying. Now it is clear that it is both a firefighter, putting out blazes, and an arsonist, fanning the flames of recombination. It is precisely this dual role that makes it a weak spot in the 10-15% of tumors that do not use telomerase.
The practical takeaway is already clear: block PIF1, and cancer cells lose the ability to repair their telomeres and pile up damage. For patients with ALT tumors, which are often resistant to standard therapy, this opens up a new drug target. But before PIF1 inhibitors reach the clinic, they need to be tested in animals and confirmed not to harm healthy cells, where this protein also does useful work.
The PIF1i inhibitor (Compound 1) was checked in the lab by HPLC, mass spectrometry, and NMR, and its purity came out close to 99%. It is a rare case of a small molecule against a helicase being so thoroughly characterized before use in cell experiments.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.